Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 18/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13805515 | 0.99 | CHRM3 (0.62) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL12725399 | 0.93 | CHRM3 (0.62) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL1630607 | 0.92 | CHRM3 (0.73) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL1630612 | 0.90 | CHRM3 (0.58) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL13805519 | 0.88 | CHRM3 (0.69) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL1632345 | 0.85 | CHRM3 (0.60) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4218341 | 0.84 | CHRM3 (0.67) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL13805520 | 0.84 | CHRM2 (0.70) | CHRM3CHRM2CHRM1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232308 | 0.84 | CHRM2 (0.71) | CHRM3CHRM2CHRM1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232310 | 0.83 | CHRM2 (0.69) | CHRM3CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM1 8/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.